Avecho Biotechnology Ltd. engages in the development, production, sale, and licensing of products incorporating its patented platform technology, Targeted Penetration Matrix (TPM), for the pharmaceutical, skin care and animal health and nutrition industries. The company is headquartered in Melbourne, Victoria. The firm’s products pipeline includes Weaner Pig Starter TPM premix, Poultry TPM, Dairy TPM, and Veterinary Applications. The firm’s segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for the use in drug delivery and cosmetic formulations. The Company’s Human Health segment covers delivery of pharmaceutical products through gels, injectables and patches. This segment focuses on the development of patches, including TPM/Oxymorphone, TPM/enhanced, and TPM/Oxycodone. The firm is also developing TPM to enhance feed efficiency and health of livestock. Its TPM products are commercialized under license Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.